Literature DB >> 16650449

Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1.

Felipe Diaz-Griffero1, Nick Vandegraaff, Yuan Li, Kathleen McGee-Estrada, Matthew Stremlau, Sohanya Welikala, Zhihai Si, Alan Engelman, Joseph Sodroski.   

Abstract

In owl monkeys, a retrotransposition event replaced the gene encoding the retroviral restriction factor TRIM5alpha with one encoding TRIMCyp, a fusion between the RING, B-box 2 and coiled-coil domains of TRIM5 and cyclophilin A. TRIMCyp restricts human immunodeficiency virus (HIV-1) infection by a mechanism dependent on the interaction of the cyclophilin A moiety and the HIV-1 capsid protein. Here, we show that infection by retroviruses other than HIV-1 can be restricted by TRIMCyp, providing an explanation for the evolutionary retention of the TRIMCyp gene in owl monkey lineages. The TRIMCyp-mediated block to HIV-1 infection occurs before the earliest step of reverse transcription. TRIMCyp-mediated restriction involves at least two functions: (1) capsid binding, which occurs most efficiently for trimeric TRIMCyp proteins that retain the coiled-coil and cyclophilin A domains, and (2) an effector function that depends upon the B-box 2 domain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650449     DOI: 10.1016/j.virol.2006.03.023

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  65 in total

1.  RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating.

Authors:  Amanda Roa; Fumiaki Hayashi; Yang Yang; Maritza Lienlaf; Jing Zhou; Jiong Shi; Satoru Watanabe; Takanori Kigawa; Shigeyuki Yokoyama; Christopher Aiken; Felipe Diaz-Griffero
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

Review 2.  Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.

Authors:  Jeremy Luban
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

3.  K63-Linked Ubiquitin Is Required for Restriction of HIV-1 Reverse Transcription and Capsid Destabilization by Rhesus TRIM5α.

Authors:  Sabrina Imam; Sevnur Kömürlü; Jessica Mattick; Anastasia Selyutina; Sarah Talley; Amani Eddins; Felipe Diaz-Griffero; Edward M Campbell
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

4.  The ability of multimerized cyclophilin A to restrict retrovirus infection.

Authors:  Hassan Javanbakht; Felipe Diaz-Griffero; Wen Yuan; Darwin F Yeung; Xing Li; Byeongwoon Song; Joseph Sodroski
Journal:  Virology       Date:  2007-06-15       Impact factor: 3.616

5.  Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha.

Authors:  Xing Li; Byeongwoon Song; Shi-Hua Xiang; Joseph Sodroski
Journal:  Virology       Date:  2007-05-31       Impact factor: 3.616

6.  Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1.

Authors:  Tsai-Yu Lin; Michael Emerman
Journal:  Virology       Date:  2008-08-03       Impact factor: 3.616

7.  Prolonged transgene expression with lentiviral vectors in the aqueous humor outflow pathway of nonhuman primates.

Authors:  Román A Barraza; Carol A Rasmussen; Nils Loewen; J Douglas Cameron; B'Ann T Gabelt; Wu-Lin Teo; Paul L Kaufman; Eric M Poeschla
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

8.  Determinants for the rhesus monkey TRIM5alpha-mediated block of the late phase of HIV-1 replication.

Authors:  Ryuta Sakuma; Seiga Ohmine; Yasuhiro Ikeda
Journal:  J Biol Chem       Date:  2009-12-01       Impact factor: 5.157

9.  Independent evolution of an antiviral TRIMCyp in rhesus macaques.

Authors:  Sam J Wilson; Benjamin L J Webb; Laura M J Ylinen; Ernst Verschoor; Jonathan L Heeney; Greg J Towers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

10.  Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.

Authors:  Cesar A Virgen; Zerina Kratovac; Paul D Bieniasz; Theodora Hatziioannou
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.